Reações de hipersensibilidade a vacinas
Hypersensitivity reactions to vaccines
Ana Karolina Barreto Berselli Marinho; Adriana Azoubel Antunes; Bianca Noleto Ayres Guimarães; Clarissa Morais Busatto Gerhardt; Claudia França Cavalcante Valente; Claudia Leiko Yonekura Anagusko; Emanuel Sarinho; Fátima Rodrigues Fernandes; Gilberto Saciloto; Gisele Feitosa Zuvanov Casado; Irma Cecilia Douglas Paes Barreto; Ronney Corrêa Mendes; Mônica de Araújo Álvares da-Silva; Aluce Loureiro Ouricuri; Lorena de Castro Diniz
Resumo
O desenvolvimento e a ampliação do uso das vacinas durante décadas contribuíram para o controle e erradicação de doenças infecciosas, causando um grande impacto na saúde pública no mundo. A análise de segurança das vacinas percorre criteriosos processos e fases dos estudos clínicos, um dos pilares essenciais para aprovação regulatória e utilização do produto na população. O evento supostamente atribuído à vacinação e imunização (ESAVI), terminologia atual, é definido como qualquer ocorrência médica indesejada após a vacinação que possui, ou não, uma relação causal com o uso de uma vacina ou outro imunobiológico. Cabe ressaltar que eventos adversos mais raros ou inesperados, incluindo os eventos de hipersensibilidade, poderão ocorrer na fase pós-comercialização, quando as vacinas são aplicadas em milhões de pessoas. Neste artigo, serão discutidos os principais aspectos relacionados aos eventos adversos de hipersensibilidade pós-vacinais de interesse do especialista, e os desafios frente ao reconhecimento do agente causal e conduta a ser adotada. Além disso, serão revisados os potenciais alérgenos presentes nas vacinas de uso rotineiro para auxiliar o profissional de saúde na identificação de pacientes com potencial de risco de ESAVI por tais componentes. A atualização do conhecimento acerca da segurança e dos benefícios das vacinas pelos profissionais de saúde, sobretudo em populações especiais, contribui para condutas em imunização mais apropriadas, reduzindo o risco de exposição a um possível alérgeno em pessoas comprovadamente alérgicas às vacinas ou a alguns dos seus componentes, além de evitar contraindicações desnecessárias em eventos coincidentes ou não graves.
Palavras-chave
Abstract
The expansion of vaccine use and development in recent decades has contributed to the control and eradication of infectious diseases, causing a major impact on public health worldwide. Vaccine safety analysis, which involves careful processes and clinical study, is one of the essential pillars of regulatory approval and use in the population. In current terminology, events supposedly attributable to vaccination and immunization (ESAVI) are defined as any unwanted medical occurrence after vaccination that may or may not have a causal relationship with vaccines or other immunobiologicals. It is noteworthy that rare or unexpected adverse events, including hypersensitivity, can occur during the post-marketing phase, when vaccines are administered to millions of people. In this article, we will discuss the main aspects of post-vaccine hypersensitivity events of interest to specialists and challenges to recognizing the causal agent and appropriate clinical practice. Potential allergens in routine vaccines will also be reviewed to help health professionals identify patients with a potential risk of ESAVI due to such components. Updating health professionals’ knowledge about the safety and benefits of vaccines, particularly in special populations, can contribute to more appropriate clinical practice regarding immunization, reducing the risk of exposure to possible allergens in people with allergies to vaccines or their components, avoiding unnecessary contraindications in coincidental or non-serious events.
Keywords
References
1. Barreto ML, Teixeira MG, Bastos FI, Ximenes RAA, Barata RB, Rodrigues LC. Sucessos e fracassos no controle de doenças infecciosas no Brasil: o contexto social e ambiental, políticas, intervenções e necessidades de pesquisa. Lancet. 2011;47-60.
2. Veve MP, Athans V. Vaccines. In: Sidhartha R, ed. Side Effects of Drugs Annual 40. Elsevier; 2018. p. 694.
3. Teuwen DE, Barrett ADT. Vaccine Safety. In: Milligan GN, Barrett ADT (eds). Vaccinology: An Essential Guide. Wiley-Blacwell; 2014. p. 400.
4. Council for International Organizations of Medical Sciences (CIOMS). Definition and Application Pharmacovigilance. Definition and Application of Terms for Vaccine Pharmacovigilance. CIOMS, WHO; 2012. p.193.
5. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Imunizações e Doenças Transmissíveis. Manual de vigilância epidemiológica de eventos adversos pós-vacinação [recurso eletrônico] - 4ª ed. - Brasília: Ministério da Saúde; 2020; p.340. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/manual_vigilancia_epidemiologica_eventos_vacinacao_4ed.pdf. Acessado em: novembro/2022.
6. Miler ER, Haber P, Hibbs B, Broder K. Surveillance for Adverse Events Following Immunization Using the Vaccine Adverse Event Reporting System (VAERS). VPD Suveillance Man. 2011;1-14.
7. Dreskin SC, Halsey NA, Kelso JMJM, Wood RA, Hummell DS, Edwards KM, et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J. 2016;9(1):32.
8. McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463-72.
9. McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868-78. doi: 10.1016/j.jaci.2015.07.048.
10. Erlewyn-Lajeunesse M, Hunt LP, Heath PT, Finn A. Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Arch Dis Child. 2012;97(6):487-90. doi: 10.1136/archdischild-2011-301163.
11. Cheng DR, Perrett KP, Choo S, Danchin M, Buttery JP, Crawford NW. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013. Vaccine. 2015;33(13):1602-7.
12. Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano M V. Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016. J Allergy Clin Immunol. 2019;143(4):1465‑73.
13. Giavina-Bianchi P, Kalil J. Polyethylene Glycol Is a Cause of IgE-Mediated Anaphylaxis. J Allergy Clin Immunol Pract. 2019;7(6):1874‑5.
14. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med. 1995;332(19):1262-6. doi: 10.1056/NEJM199505113321904.
15. Baxter DN. Measles immunization in children with a history of egg allergy. Vaccine. 1996;14(2):131-4.
16. Kelso JM. Administering influenza vaccine to egg-allergic persons. Expert Rev Vaccines. 2014;13(8):1049-57. doi: 10.1586/14760584.2014.933079.
17. Marinho AKBB, Ouricuri AL, Valente CFC, Fernandes FR, Saciloto G, Diniz L de C, et al. Vacina contra a febre amarela: reações adversas e populações de risco. Arq Asma, Alerg e Imunol. 2017;1(3):245‑56.
18. Gerhardt CMB, Feitosa G de SJ, Aquilante BP, Dorna M de B, Santos C de JN dos, Pastorino AC. Segurança da vacina de febre amarela em pacientes comprovadamente alérgicos à proteína do ovo. Arq Asma, Alerg e Imunol. 2019;3(2):143‑50.
19. Fantinato FFST, Vargas A, Carvalho SMD, Domingues CMAS, Barreto G, Fialho AS, et al. Anafilaxia relacionada à vacina sarampo, caxumba e rubéola, Santa Catarina, Brasil, 2014 e 2015. Cad Saude Publica. 2018;34(3):e00043617. doi: 10.1590/0102-311X00043617.
20. Piñones M, Landaeta M, Bustos P, Toche P, Morales P, Escobar C, et al. Hypersensitivity reactions to measles-mumps-rubella vaccine in patients with IgE-mediated cow's milk allergy. J Allergy Clin Immunol Pract. 2020;8(1):349-51.
21. Kattan JD, Konstantinou GN, Cox AL, Nowak-Węgrzyn A, Gimenez G, Sampson HA, et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow's milk allergy. J Allergy Clin Immunol. 2011 Jul;128(1):215-8. doi: 10.1016/j.jaci.2011.04.046.
22. Nilsson L, Brockow K, Alm J, Cardona V, Caubet JC, Gomes E, et al. Vaccination and allergy: EAACI position paper, practical aspects. Pediatr Allergy Immunol. 2017;28(7):628‑40. doi: 10.1111/pai.12762.
23. Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol. 1996;98(6 Pt 1):1058‑61.
24. Kelso JM, Jones RT, Yunginger JW. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy Clin Immunol. 1993;91(4):867‑72.
25. Kumagai T, Yamanaka T, Wataya Y, Umetsu A, Kawamura N, Ikeda K, et al. Gelatin-specific humoral and cellular immune responses in children with immediate- and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines. J Allergy Clin Immunol. 1997;100(1):130‑4.
26. Sakaguchi M, Yamanaka T, Ikeda K, Sano Y, Fujita H, Miura T, et al. IgE-mediated systemic reactions to gelatin included in the varicella vaccine. J Allergy Clin Immunol. 1997;99(2):263‑4.
27. Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, Yunginger JW, et al.; VAERS Team. US Vaccine Adverse Event Reporting System. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics. 2002;110(6):e71. doi: 10.1542/peds.110.6.e71.
28. DiMiceli L, Pool V, Kelso JM, Shadomy SV, Iskander J. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine 2006;24(6):703‑7.
29. Blumenthal KG, Robinson LB, Camargo CA Jr, Shenoy ES, Banerji A, Landman AB, et al. Acute Allergic Reactions to mRNA COVID-19 Vaccines. JAMA. 2021;325(15):1562‑5. doi: 10.1001/jama.2021.3976.
30. Bigini P, Gobbi M, Bonati M, Clavenna A, Zucchetti M, Garattini S, et al. The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines. Nat Nanotechnol. 2021;16(11):1169‑71. doi: 10.1038/s41565-021-01001-3.
31. Des Roches A, Graham F, Begin P, Paradis L, Gold M. Evaluation of Adverse Reactions to Vaccines. J Allergy Clin Immunol Pract. 2021;9(10):3584‑97.
32. Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic Purpura after Measles-Mumps-Rubella Vaccination: A Systematic Review of the Literature and Guidance for Management. J Pediatr. 2010;156(4):623‑8.
33. Peng B, Wei M, Zhu FC, Li JX. The vaccines-associated Arthus reaction. Hum Vaccin Immunother. 2019;15(11):2769‑77.
34. Fishbein DB, Yenne KM, Dreesen DW, Teplis CF, Mehta N, Briggs DJ. Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: A nationwide prospective study. Vaccine. 1993;11(14):1390‑4.
35. Bergfors E, Trollfors B, Inerot A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine. 2003;22(1):64‑9.
36. Bergfors E, Trollfors B. Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines-prognosis and outcome after booster vaccination. Eur J Pediatr. 2013;172(2):171‑7.
37. SBIM/ASBAI. Guia de Imunização SBIm/ASBAI - Asma, Alergia e Imunodeficiências 2020-2021 [Internet]. 2020. Disponível em: https://sbim.org.br/images/guias/guia-sbim-asbai-miolo-201013b-web.pdf. Acessado em: novembro/2022.
38. ASBAI. Posicionamento da ASBAI em relação à aplicação de vacina Influenza em pacientes alérgicos ao ovo [Internet]. 2016. Disponível em: http://www.sbai.org.br/imagebank/2016-09-26-PARECER-VACINA-INFLUENZA-X-ALERGIA-OVO-ASBAI-2016-Fatima.pdf. Acessado em: novembro/2022.
39. Brasil. Ministério da Saúde. Crianças ainda devem ser vacinadas contra sarampo e poliomielite em 2015 [Internet]. 2014 Disponível em: http://portalms.saude.gov.br/noticias/svs/16091-estados-que-nao-atingiram-meta-devem-continuar-vacinando. Acessado em: novembro/2022.
40. Ozaki T, Nishimura N, Muto T, Sugata K, Kawabe S, Goto K, et al. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan. Vaccine. 2005;23(10):1205‑8.
41. Huu TN, Toan NT, Tuan HM, Viet HL, Le Thanh Binh P, Yu TW, et al. Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial. BMC Infect Dis. 2013;13(1):95.
42. Ponvert C, Scheinmann P, de Blic J. Anaphylaxis to the 23-valent pneumococcal vaccine: a second explored case by means of immediate-reading skin tests with pneumococcal vaccines. Vaccine. 2010;28(52):8256-7.
43. Ponvert C, Ardelean-Jaby D, Colin-Gorski AM, Soufflet B, Hamberger C, De Blic J, et al. Anaphylaxis to the 23-valent pneumococcal vaccine in child: A case-control study based on immediate responses in skin tests and specific IgE determination. Vaccine. 2001;19(32):4588‑91.
44. Arroabarren E, Anda M, Sanz ML. Anaphylaxis to pneumococcal vaccine; CRM(197): Novel cause of vaccine allergy. Pediatr Allergy Immunol. 2016;27(4):433‑7.
45. Ponvert C. Les réactions d'hypersensibilité allergique et non allergique aux vaccins contenant des anatoxines. Arch Pédiatrie. 2009;16(4):391‑5.
46. Nakayama T, Aizawa C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. J Allergy Clin Immunol. 2000;106(3):591‑2.
47. Netterlid E, Hindsén M, Björk J, Ekqvist S, Güner N, Henricson KÅ, et al. There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hyposensitization therapy. Contact Dermatitis. 2009;60(1):41‑9.
48. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020;382(21):1969‑73.
49. Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101‑2.
50. Kelso JM. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines. Ann Allergy Asthma Immunol. 2021;127(1):133‑4.
51. Delayed Large Local Reactions to mRNA Vaccines. N Engl J Med. 2021;384(24):e98.
52. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403‑16.
53. Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2. N Engl J Med. 2021;384(13):1273‑7.
54. Banerji A, Wickner PG, Saff R, Stone CA, Robinson LB, Long AA, et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach - PubMed [Internet]. Vol. 9; p. 1423-37. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33388478/. Acessado em: 25/10/2022.
55. Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, et al. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14(2):100517.
56. Altrichter S, Wöhrl S, Horak F, Idzko M, Jordakieva G, Untersmayr E, et al. Answers to burning questions for clinical allergologists related to the new COVID-19 vaccines. Allergo J Int. 2021;30(5):169‑75.
57. Tuzer C, Terzioglu K. Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines. Int Arch Allergy Immunol. 2022;183(6):651-61. doi: 10.1159/000521709.
58. Bellinato F, Fratton Z, Girolomoni G, Gisondi P. Cutaneous Adverse Reactions to SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. Vaccines (Basel). 2022;10(9):1475. doi: 10.3390/vaccines10091475.
59. Durmaz K, Aykut Temiz S, Metin Z, Dursun R, Abdelmaksoud A. Allergic and cutaneous reactions following inactivated SARS-CoV-2 vaccine (CoronaVac®) in healthcare workers. Clin Exp Dermatol. 2022;47(1):171‑3.
60. Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130(1):25‑43.
61. Caubet JC, Rudzeviciene O, Gomes E, Terreehorst I, Brockow K, Eigenmann PA. Managing a child with possible allergy to vaccine. Pediatr Allergy Immunol. 2014;25(4):394‑403.
62. Wood RA, Berger M, Dreskin SC, Setse R, Engler RJ, Dekker CL, et al.; Hypersensitivity Working Group of the Clinical Immunization Safety Assessment (CISA) Network. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008;122(3):e771-7. doi: 10.1542/peds.2008-1002.
63. Wood RA, Setse R, Halsey N. Irritant skin test reactions to common vaccines. J Allergy Clin Immunol. 2007;120(2):478‑81.
64. Michalska-Krzanowska G. Tryptase in diagnosing adverse suspected anaphylactic reaction. Adv Clin Exp Med. 2012;21(3):403-8.
65. Sociedade Brasileira de Imunizações (SBIm). Nota Técnica: recuperação de esquemas de doses atrasados em decorrência da pandemia - SBIm [Internet]. 2020. Disponível em: https://sbim.org.br/images/files/notas-tecnicas/nt-sbim-recuperacao-doses-atrasadas-pandemia-v2.pdf. Acessado em: novembro/2022.
Submitted date:
11/28/2022
Accepted date:
02/11/2023
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email